

09/ 336 672
A/H# 29

WEST Search History

DATE: Friday, December 06, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
L7	l5 and l6	221	L7
L6	l2 or l4	6444	L6
L5	(insulin b) or (ins b) or insb	8575	L5
L4	il4 or (il 4) or (interleukin 4)	5538	L4
L3	l1 and L2	50	L3
L2	il10 or (il 10) or (interleukin 10)	2856	L2
L1	gad	1239	L1

END OF SEARCH HISTORY

WEST**Print Selection**

Select?	Document ID	Section(s)	Page(s)	# Pages to print	Database
<input checked="" type="checkbox"/>	20020119159	all	all	17	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	6207159	all	all	14	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	5891435	all	all	13	USPT,PGPB,JPAB,EPAB,DWPI

Building**Room****Printer**

cm1



11e14



gbegptr



WEST**Print Selection**[Help](#)[Clear](#)[Cancel](#)[Print](#)[Print First Page](#)

Select?	Document ID	Section(s)	Page(s)	# Pages to print	Database
<input checked="" type="checkbox"/>	6207159	all	all	14	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	6488933	all	all	16	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	6277635	all	all	* 52	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	5783567	all	all	42	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	5935577	all	all	22	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	5951976	all	all	20	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	6218133	all	all	11	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	20020098194	all	all	7	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	5891435	all	all	13	USPT,PGPB,JPAB,EPAB,DWPI

Note: Print requests for more than 49 pages are denoted by '*' and are in red.

Building**Room****Printer**

cm1 ▼

11e14 ▼

gbegptr ▼

[Main Menu](#)[Logout](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 50 of 50 returned.**

-
- ☐ 1. [20020182258](#). 18 Jul 01. 05 Dec 02. Microparticles for delivery of nucleic acid. Lunsford, Lynn B., et al. 424/499; 435/320.1 514/44 A61K048/00 A61K009/50.
-
- ☐ 2. [20020155596](#). 29 Nov 01. 24 Oct 02. Recombinant vaccinia virus incorporated with gene coding glutamic acid decarboxylase and vaccine for preventing type 1 diabetes mellitus comprising the same. Yoon, Ji Won, et al. 435/320.1; 424/199.1 424/232.1 435/235.1 536/23.5 C07H021/04 A61K039/12 A61K039/275 A61K039/285 C12N007/00 C12N007/01 C12N015/00 C12N015/63 C12N015/70 C12N015/74 C12N015/09.
-
- ☐ 3. [20020146396](#). 11 Dec 01. 10 Oct 02. Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells. Albert, Matthew L., et al. 424/93.21; 435/366 435/456 A61K048/00 C12N005/08 C12N015/86.
-
- ☐ 4. [20020142004](#). 07 Jan 02. 03 Oct 02. Immunoreactive and immunotherapeutic molecules. Harrison, Leonard, et al. 424/185.1; 514/12 530/350 A61K039/00 A61K038/16 C07K014/00.
-
- ☐ 5. [20020131962](#). 30 Apr 02. 19 Sep 02. Method of producing dendritic cells. Waldmann, Herman, et al. 424/93.21; 424/93.7 435/372 A61K048/00 C12N005/08.
-
- ☐ 6. [20020115696](#). 18 Dec 01. 22 Aug 02. Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists. Kloog, Yoel, et al. 514/345; 514/352 514/567 A61K031/44 A61K031/195.
-
- ☐ 7. [20020115103](#). 23 Mar 01. 22 Aug 02. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use. Gad, Alexander, et al. 435/7.1; 530/350 G01N033/53 C07K014/00.
-
- ☐ 8. [20020106368](#). 30 Jul 01. 08 Aug 02. Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same. Bot, Adrian, et al. 424/130.1; 514/2 A61K039/395 A61K038/22.
-
- ☐ 9. [20020103165](#). 29 Feb 00. 01 Aug 02. Engineered spray-dried lipid-based microparticles for cellular targeting. Bot, Adrian, et al. 514/100; A61K031/665.
-
- ☐ 10. [20020102604](#). 07 Dec 00. 01 Aug 02. Full-length human cDNAs encoding potentially secreted proteins. Milne Edwards, Jean-Baptiste Dumas, et al. 435/7.1; 530/350 536/23.1 G01N033/53 C07H021/02 C07H021/04 C07K001/00 C07K014/00 C07K017/00.
-
- ☒ 11. [20020098194](#). 21 Mar 96. 25 Jul 02. METHODS FOR INDUCING IMMUNITY. LEHMANN, PAUL V., et al. 424/184.1; 435/325 435/7.21 G01N033/567 A61K039/00 A61K039/38 C12N005/00 C12N005/02.
-
- ☐ 12. [20020090357](#). 03 Oct 01. 11 Jul 02. Regulatory T cells; methods. Barrat, Franck J., et al. 424/93.7; 514/167 514/179 A61K045/00 A61K031/59.
-

-
- ☐ 13. 20020086030. 19 Apr 98. 04 Jul 02. PREPARATIONS AND METHODS FOR THE TREATMENT OF T CELL MEDIATED DISEASES. COHEN, IRUN R, et al. 424/185.1; 424/248.1 514/13 A61K039/38 A61K039/00 A61K039/04 A61K038/00.
-
- ☐ 14. 20020068715. 05 Sep 01. 06 Jun 02. DNA vaccination for treatment of autoimmune disease. Steinman, Lawrence, et al. 514/44; 424/85.2 435/320.1 A61K048/00.
-
- ☐ 15. 20020034500. 14 Aug 01. 21 Mar 02. Regulatory T cells; methods. Levings, Megan K., et al. 424/93.7; 424/85.7 A61K038/21 A61K045/00.
-
- ☐ 16. 20020031787. 02 Feb 01. 14 Mar 02. Compositions and methods for reducing autoimmunity. Maclaren, Noel K., et al. 435/7.21; G01N033/567.
-
- ☐ 17. 20020019047. 04 May 01. 14 Feb 02. Method for producing dendritic cells. Waldmann, Herman, et al. 435/372; C12N005/08.
-
- ☐ 18. 20020015698. 16 Apr 01. 07 Feb 02. Prophylaxis and therapy of diabetes mellitus I with the help of proteolytic enzymes. Ransberger, Karl, et al. 424/94.65; 514/27 A61K038/43 A61K038/46.
-
- ☐ 19. 20020009730. 13 Feb 01. 24 Jan 02. Human stress array. Chenchik, Alex, et al. 435/6; 536/24.3 C12Q001/68 C07H021/04.
-
- ☐ 20. 20020001841. 25 Jun 99. 03 Jan 02. CONTINUOUS T-CELL LINES. KALTOFT, KELD, et al. 435/366; 435/372.3 A61K039/395 A61K039/40 A61K039/42 A61K039/44 C12N005/08.
-
- ☐ 21. 20010036917. 30 May 01. 01 Nov 01. Therapeutic agents. Williams, Neil Andrew, et al. 514/3; 514/54 A61K038/28 A61K031/726.
-
- ☐ 22. 20010021510. 29 Mar 01. 13 Sep 01. Materials and methods for detection and treatment of immune system dysfunctions. Clare-Salzer, Michael. 435/7.1; 514/420 G01N033/53 A61K031/405.
-
- ☒ 23. 6488933. 19 Apr 98; 03 Dec 02. Preparations for the treatment of T cell mediated diseases. Cohen; Irun R., et al. 424/185.1; 424/184.1 424/248.1 424/283.1 514/13. A61K039/00.
-
- ☐ 24. 6479258. 31 Jan 00; 12 Nov 02. Non-stochastic generation of genetic vaccines. Short; Jay M.. 435/69.1; 530/350 536/23.2. C12P021/06 C07K001/00 C07H021/04.
-
- ☐ 25. 6403080. 24 Jun 99; 11 Jun 02. Methods of modulating an immune response to antigen, and cells for use in the method. Segal; Andrew H.. 424/93.1; 424/136.1 424/93.2 424/93.21 424/93.7 424/93.71 435/325 514/12 514/2 530/387.3. A01N063/00 A61K039/395 A61K038/00 C12P021/08.
-
- ☐ 26. 6361771. 05 Apr 00; 26 Mar 02. ARPE-19 as a platform cell line for encapsulated cell-based delivery. Tao; Weng, et al. 424/93.21; 435/320.1 435/325 435/366 435/371 435/455 604/43 604/890.1 623/4.1. A61K048/00 A61K009/22 C12N015/163 C12N005/108 A61M003/00.
-
- ☐ 27. 6335170. 22 Feb 00; 01 Jan 02. Gene expression in bladder tumors. Orntoft; Torben F.. 435/6; 435/91.1 435/91.2 536/23.1 536/24.3 536/24.31 536/24.33. C12Q001/68 C12P019/34 C07H021/02.
-

- ☐ 28. 6309847. 22 Jul 98; 30 Oct 01. Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases. Cohen; Irun R., et al. 435/7.24; 424/9.2 435/7.94 436/506. A61K049/00 G01N033/53.
-
- ☒ 29. 6277635. 06 May 96; 21 Aug 01. Use of interleukin-10 to produce a population of suppressor cells. Roncarolo; Maria-Grazia, et al. 435/372.3; 435/325 435/366 435/372. C12N005/08.
-
- ☒ 30. 6218133. 28 May 99; 17 Apr 01. Materials and methods for detection and treatment of immune system dysfunctions. Clare-Salzler; Michael. 435/7.24; 435/25 435/6 435/7.4 436/506 436/63 436/71 436/86. C12Q001/26 C12Q001/68 G01N033/564 G01N033/573 G01N033/88.
-
- ☐ 31. 6218132. 24 Nov 97; 17 Apr 01. Method for monitoring T cell reactivity. Spack; Edward G., et al. 435/7.24; 435/7.94 435/7.95 436/506. G01N033/53 G01N033/564.
-
- ☒ 32. 6207159. 21 Jul 98; 27 Mar 01. Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus. Kaufman; Daniel L., et al. 424/184.1; 424/278.1 424/283.1 424/520 424/556 424/572 424/810 424/93.7 514/2 514/21 514/3 514/4 514/866 530/351 530/403. A61K039/00 A61K045/00 A61K038/28 A61K038/43 A01N063/00.
-
- ☐ 33. 6180103. 07 Aug 97; 30 Jan 01. Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes. Cohen; Irun R., et al. 424/185.1; 424/184.1 424/198.1 435/7.1 435/7.92 435/975 436/506 436/518 436/536 436/543 436/811 514/13 514/2 514/885 530/325. A61K038/16 A61K039/00 C07K014/00 G01N033/53.
-
- ☐ 34. 6171856. 30 Jul 98; 09 Jan 01. Methods and compositions relating to no-mediated cytotoxicity. Thigpen; Anice, et al. 435/325; 424/196.11 424/204.1 424/93.21 424/93.3 424/94.4 435/14 435/176 435/183 435/234 435/235.1 435/252.3 435/254.11 435/3 435/30 435/317.1 435/320.1 435/34 435/366 435/372.3 435/375 435/440 435/455 435/465 435/69.1 435/69.4 435/69.7 514/10 514/14 514/169 514/31 514/564 514/806 514/9. C12N015/00.
-
- ☐ 35. 6168792. 22 Aug 97; 02 Jan 01. Materials and methods for detection and treatment of immune system dysfunctions. Clare-Salzler; Michael. 424/184.1; 424/278.1 424/810 424/85.2 514/415 514/605 514/866 514/885. A61K031/18 A61K031/405 A61K039/00.
-
- ☐ 36. 6162609. 17 Dec 98; 19 Dec 00. Diagnostic and therapeutic methods based upon V.alpha.24J.alpha.QT cells. Hafler; David A., et al. 435/7.24; 435/29 435/372.3 435/7.92 530/351. G01N033/53.
-
- ☐ 37. 6150584. 02 Oct 96; 21 Nov 00. Human antibodies derived from immunized xenomice. Kucherlapati; Raju, et al. 800/18; 424/93.21 800/25 800/6. A61K048/00 C12N005/10 C12N015/07.
-
- ☐ 38. 6110746. 27 Apr 98; 29 Aug 00. Peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits. Cohen; Irun R., et al. 436/506; 436/542 530/326 530/350 530/827 530/868. G01N033/564 G01N033/536 C07K007/08 C07K014/00.
-
- ☐ 39. 6075181. 07 Jun 95; 13 Jun 00. Human antibodies derived from immunized xenomice. Kucherlapati; Raju, et al. 800/25; 800/18 800/21 800/4 800/6. A61K048/00 C12N015/09 C12N005/10.
-
- ☐ 40. 6040134. 15 Jul 97; 21 Mar 00. Method of diagnosing preclinical diabetes. Madsen; Ole

Dragsbaek, et al. 435/4; 435/372.3 435/6 435/7.1 435/7.2 435/7.24 435/7.7 435/7.72 435/7.9 435/7.92
435/965 435/975 436/503 436/506 436/63 530/350 530/387.1 530/391.3 530/395. G01N033/50
G01N033/53 G01N033/564 G01N033/567.

☐ 41. 6022697. 09 Jul 97; 08 Feb 00. Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus. Kaufman; Daniel L., et al. 435/7.24; 435/7.92 436/501 436/506 530/350 530/351. G01N033/53 G01N033/564 C07K001/00.

☐ 42. 5993803. 30 Aug 96; 30 Nov 99. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity. Cohen; Irun R., et al. 424/93.71; 424/185.1 424/283.1 514/12 514/21. A61K039/00 A61K038/00 A01N063/00.

☒ 43. 5951976. 27 Mar 97; 14 Sep 99. Opsonin-enhanced cells, and methods of modulating an immune response to an antigen. Segal; Andrew H.. 424/93.21; 424/93.7 435/325 514/12 514/21. A61K038/00 C12N009/00 C12N005/06 A01N063/00.

☐ 44. 5945401. 23 Jun 95; 31 Aug 99. Peptide analogues of the 65KD isoform of human glutamic acid decarboxylase and uses thereof. Conlon; Paul J., et al. 514/14; 530/323 530/326 530/327 530/329. A61K038/43.

☐ 45. 5939069. 23 Aug 96; 17 Aug 99. Materials and methods for detection and treatment of immune system dysfunctions. Clare-Salzler; Michael. 424/184.1; 424/278.1 424/810 436/71 514/415 514/605 514/866 514/885. A61K031/18 A61K031/405 A61K039/00.

☒ 46. 5935577. 23 Jan 98; 10 Aug 99. Treatment of autoimmune disease using tolerization in combination with methotrexate. Weiner; Howard L., et al. 424/184.1; 424/810 514/2 514/21 514/249 514/3 514/4 514/826 514/866 514/885 514/903. A61K039/00 A61K038/17 A61K038/28 A61K038/00.

☒ 47. 5891435. 16 Apr 93; 06 Apr 99. Methods and compositions for delaying or preventing the onset of autoimmune disease. Muir; Andrew, et al. 424/185.1; 424/198.1 530/300 530/350 530/399. A61K038/28.

☒ 48. 5783567. 22 Jan 97; 21 Jul 98. Microparticles for delivery of nucleic acid. Hedley; Mary Lynne, et al. 514/44; 435/320.1 536/23.1. A61K048/00 C12N015/63 C12N015/11.

☐ 49. 5750356. 31 May 96; 12 May 98. Method for monitoring T cell reactivity. Spack; Edward G., et al. 435/7.24; 435/7.94. G01N033/53.

☐ 50. 5624895. 18 Feb 94; 29 Apr 97. Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration. Sobel; Douglas. 514/8; 424/85.1 424/85.2 424/85.4 424/85.5 424/85.6 424/85.7 514/866. A61K038/10 A61K038/19 A61K038/20 A61K038/21.

Generate Collection

Print

Terms	Documents
11 and L2	50

[Previous Page](#)

[Next Page](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 50 of 221 returned.**

-
- ☐ 1. [20020177572](#). 25 Oct 01. 28 Nov 02. Viral infection of cells. Feldmann, Marc, et al. 514/44; 424/93.21 435/456 A61K048/00 C12N015/861.
-
- ☐ 2. [20020177135](#). 11 Jul 01. 28 Nov 02. Devices and methods for biochip multiplexing. Doung, Hau H., et al. 435/6; 435/287.2 C12Q001/68 C12M001/34.
-
- ☐ 3. [20020173552](#). 22 Feb 02. 21 Nov 02. Erodible polymers for injection. Cleland, Jeffrey L., et al. 514/772.3; A61K047/30.
-
- ☐ 4. [20020165183](#). 13 Nov 01. 07 Nov 02. Methods for genetic immunization. Herweijer, Hans, et al. 514/44; 424/45 424/474 A61K048/00 A61L009/04 A61K009/28.
-
- ☐ 5. [20020164743](#). 28 Sep 01. 07 Nov 02. Novel cytidine deaminase. Honjo, Tasuku, et al. 435/191; 435/320.1 435/325 435/6 435/69.1 536/23.2 C12N009/06 C12Q001/68 C07H021/04 C12P021/02 C12N005/06.
-
- ☐ 6. [20020164716](#). 20 Nov 01. 07 Nov 02. Novel TNF receptor death domain ligand proteins and inhibitors of ligand binding. Lin, Lih-Ling, et al. 435/69.5; 435/320.1 435/325 435/6 530/351 536/23.5 C12Q001/68 C07H021/04 C12P021/02 C12N005/06 C07K014/52.
-
- ☐ 7. [20020155569](#). 07 Mar 01. 24 Oct 02. Regulation of gene expression through manipulation of mRNA splicing and its uses. Kaempfer, Raymond, et al. 435/194; 514/44 536/23.2 A61K048/00 C07H021/04 C12N009/12.
-
- ☐ 8. [20020155537](#). 07 Dec 01. 24 Oct 02. Method for making heteromultimeric polypeptides. Carter, Paul J., et al. 435/69.1; 435/320.1 435/325 C12P021/02 C12N005/06.
-
- ☐ 9. [20020155525](#). 14 Apr 99. 24 Oct 02. PROTEIN SECRETION. ASHKENAZI, AVI J., et al. 435/69.1; C12P021/06.
-
- ☐ 10. [20020142388](#). 07 Dec 01. 03 Oct 02. Bacterial host strains. Chen, Christina Yu-Ching. 435/69.1; 435/252.33 C12P021/02 C12N001/21.
-
- ☐ 11. [20020142004](#). 07 Jan 02. 03 Oct 02. Immunoreactive and immunotherapeutic molecules. Harrison, Leonard, et al. 424/185.1; 514/12 530/350 A61K039/00 A61K038/16 C07K014/00.
-
- ☐ 12. [20020137697](#). 24 Oct 95. 26 Sep 02. CHIMERIC RECEPTOR GENES AND CELLS TRANSFORMED THEREWITH. ESHHAR, ZELIG A., et al. 514/44; 424/130.1 424/134.1 424/277.1 435/320.1 435/325 435/69.1 536/23.1 A61K048/00 C07H021/04 A61K039/395 C12P021/02.
-
- ☐ 13. [20020136738](#). 23 Mar 01. 26 Sep 02. Process for the preparation of a vaccine for the treatment of tuberculosis and other intracellular infections diseases and the vaccine produced by the process. Agrewala, Javed Naim, et al. 424/201.1; 424/258.1 A61K039/295 A61K039/112.
-

- ☐ 14. 20020123337. 28 Dec 00. 05 Sep 02. System for fast macrodiversity switching in mobile wireless networks. Dharia, Bhupal Kanaiyalal, et al. 455/423; 455/137 455/277.1 H04Q007/20.
-
- ☐ 15. 20020121314. 01 May 01. 05 Sep 02. Target analyte detection using asymmetrical self-assembled monolayers. Tao, Chunlin, et al. 148/251; C23C022/00.
-
- ☒ 16. 20020119159. 22 Apr 98. 29 Aug 02. COMBINATIONS OF ANTIGEN AND MUCOSAL BINDING COMPONENT FOR INDUCING SPECIFIC IMMUNOLOGICAL TOLERANCE. PETERSEN, JACOB STEN. 424/184.1; A61K039/00 A61K039/38 A61K039/106.
-
- ☐ 17. 20020107210. 17 Jun 99. 08 Aug 02. COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DIABETES. HERRATH, MATTHIAS G. VON. 514/44; A61K048/00.
-
- ☐ 18. 20020106688. 05 Aug 97. 08 Aug 02. IDENTIFICATION OF GENE SEQUENCES AND GENE PRODUCTS AND THEIR SPECIFIC FUNCTION AND RELATIONSHIP TO PATHOLOGIES IN A MAMMAL. JENBOUBI, MONCEF. 435/7.1; G01N033/53.
-
- ☐ 19. 20020106368. 30 Jul 01. 08 Aug 02. Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same. Bot, Adrian, et al. 424/130.1; 514/2 A61K039/395 A61K038/22.
-
- ☐ 20. 20020103345. 24 May 01. 01 Aug 02. Bispecific immunoglobulin-like antigen binding proteins and method of production. Zhu, Zhenping. 530/388.15; C07K016/42.
-
- ☐ 21. 20020103165. 29 Feb 00. 01 Aug 02. Engineered spray-dried lipid-based microparticles for cellular targeting. Bot, Adrian, et al. 514/100; A61K031/665.
-
- ☐ 22. 20020081723. 18 Jun 99. 27 Jun 02. NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR MANUFACTURE AND THERAPUTIC USE THEREOF. BRAMS, PETER. 435/339; A61K039/395 C12N005/06 C12N005/16.
-
- ☐ 23. 20020081659. 10 Aug 01. 27 Jun 02. Nucleic acids, proteins and antibodies. Rosen, Craig A., et al. 435/69.1; 435/320.1 435/325 435/6 435/7.1 530/350 536/23.5 C12Q001/68 G01N033/53 C07H021/04 C12P021/02 C07K014/435 C12N005/06.
-
- ☐ 24. 20020081313. 05 Feb 01. 27 Jun 02. Aromatic amino acid decarboxylase proteins of a parasitic helminth, nucleic acid molecules coding them, and uses thereof. Tang, Liang. 424/191.1; 435/226 435/320.1 435/325 435/69.3 536/23.2 A61K039/00 C07H021/04 C12N009/64 C12P021/02 C12N005/06.
-
- ☐ 25. 20020068715. 05 Sep 01. 06 Jun 02. DNA vaccination for treatment of autoimmune disease. Steinman, Lawrence, et al. 514/44; 424/85.2 435/320.1 A61K048/00.
-
- ☐ 26. 20020062010. 23 May 01. 23 May 02. Method for making multispecific antibodies having heteromultimeric and common components. Arathoon, W. Robert, et al. 530/388.1; 435/326 435/69.1 435/70.21 C12P021/02 C12P021/04 C12N005/06 C07K016/00.
-
- ☐ 27. 20020058614. 22 Mar 01. 16 May 02. Use of insulin for the treatment of cartilaginous

disorders. Filvaroff, Ellen H., et al. 514/3; A61K038/28.

☐ 28. 20020058324. 27 Aug 01. 16 May 02. Protein recovery. Blank, Gregory S., et al. 435/226; 530/388.1 C12N009/64 C07K016/00.

☐ 29. 20020058029. 18 Sep 01. 16 May 02. Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination. Hanna, Nabil. 424/131.1; 424/144.1 A61K039/395.

☐ 30. 20020054878. 01 Aug 01. 09 May 02. Anti-IgE antibodies. Lowman, Henry B., et al. 424/171.1; 424/130.1 424/133.1 435/7.1 530/387.3 536/23.53 G01N033/53 C07H021/04 A61K039/395 A61K039/40 A61K039/42 C12P021/08.

☐ 31. 20020045571. 04 Oct 01. 18 Apr 02. Reduced-viscosity concentrated protein formulations. Liu, Jun, et al. 514/2; A61K031/17.

☐ 32. 20020042414. 17 Oct 01. 11 Apr 02. Diamide compound and medicine containing the same. Ishiwata, Hiroyuki, et al. 514/218; 514/249 540/575 544/295 544/350 A61K031/551 A61K031/506 A61K031/4985 C07D243/08.

☐ 33. 20020039557. 20 Jun 01. 04 Apr 02. Treatment of B-cell associated diseases such as malignances and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination. White, Christine. 424/1.49; 424/143.1 A61K051/00 A61K039/395.

☐ 34. 20020037280. 03 May 01. 28 Mar 02. Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof. Lieber, Andre, et al. 424/93.21; 435/235.1 435/320.1 435/456 A61K048/00 C12N007/00 C12N015/861.

☐ 35. 20020032317. 26 Sep 01. 14 Mar 02. Protein purification. Blank, Gregory S.. 530/413; C07K001/22.

☐ 36. 20020031787. 02 Feb 01. 14 Mar 02. Compositions and methods for reducing autoimmunity. Maclaren, Noel K., et al. 435/7.21; G01N033/567.

☐ 37. 20020028178. 16 May 01. 07 Mar 02. Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/1.49; 424/143.1 A61K039/395 A61K051/00.

☐ 38. 20020012665. 02 Apr 01. 31 Jan 02. Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma. Hanna, Nabil. 424/145.1; A61K039/395.

☐ 39. 20020010319. 26 May 99. 24 Jan 02. SEPARATION OF POLYPEPTIDE MONOMERS. ANSALDI, DEBORAH ANN, et al. 530/387.1; C07K016/00.

☐ 40. 20020009444. 25 Apr 01. 24 Jan 02. Intrathecal administration of rituximab for treatment of central nervous system lymphomas. Grillo-Lopez, Antonio J.. 424/142.1; 424/1.49 424/1.65 514/251 514/283 A61K051/10 A61K039/395 A61K051/04 A61K031/525 A61K031/475.

☐ 41. 20020006404. 31 Jan 01. 17 Jan 02. Treatment of cell malignancies using combination of B

cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/142.1; 424/155.1 A61K039/395.

☐ 42. 20020004587. 20 Mar 01. 10 Jan 02. Multivalent antibodies and uses therefor. Miller, Kathy L., et al. 530/388.8; 424/143.1 435/325 435/334 536/23.5 C07K016/28 A61K039/395 C07H021/04 C12N005/06.

☐ 43. 20020004227. 09 Apr 01. 10 Jan 02. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method. Ashkenazi, Avi J., et al. 435/69.1; 435/325 530/388.22 536/23.5 C12P021/02 C07H021/04 C12N005/06 C07K016/28.

☐ 44. 20020001798. 20 Dec 00. 03 Jan 02. Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof. Brams, Peter, et al. 435/5; 424/142.1 530/388.15 C12Q001/70 A61K039/395 C07K016/08.

☐ 45. 20010031263. 15 Oct 99. 18 Oct 01. METHOD AND COMPOSITION FOR TREATING PARAMYXOVIRUS. PANUSKA, JAMES R., et al. 424/184.1; 424/130.1 424/204.1 514/2 A61K039/00 A61K039/12 A61K039/395 A01N037/18 A01N061/00.

☐ 46. 20010014326. 14 Mar 01. 16 Aug 01. Protein formulation. Andya, James, et al. 424/130.1; 514/53 A61K039/395.

☐ 47. 20010010922. 30 Jun 98. 02 Aug 01. CLONING AND USES OF THE GENETIC LOCUS BCL-6. DALLA-FAVERA, RICCARDO, et al. 435/7.23; 424/130.1 514/2 514/7 A01N037/18 A61K038/00 C12Q001/68 A61K038/16 G01N033/574 A61K039/395.

☐ 48. 6489447. 03 May 99; 03 Dec 02. Protein purification. Basey, Carol D., et al. 530/387.1; 530/387.3 530/387.7 530/388.85 530/389.7 530/402 530/416. C07K001/18 C07K016/00.

☐ 49. 6488929. 12 Jul 99; 03 Dec 02. Candida albicans phosphomannan complex as a vaccine. Cutler, Jim E., et al. 424/137.1; 424/141.1 424/152.1 530/387.5 530/388.1 530/388.2 530/388.5 530/389.1 530/389.5. A61K039/395 A61K039/40 C07K016/00 C12P021/08.

☐ 50. 6479055. 06 Jun 95; 12 Nov 02. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission. Bolognesi, Dani Paul, et al. 424/211.1; 424/186.1 530/324. A61K039/145.

Generate Collection

Print

Terms	Documents
15 and 16	221

[Previous Page](#)

[Next Page](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 51 through 100 of 221 returned.**

☐ 51. [6468528](#). 01 Feb 00; 22 Oct 02. Materials and methods to inhibit Hodgkin and Reed Sternberg cell growth. Mak; Tak W., et al. 424/130.1; 424/133.1 424/141.1 424/142.1 424/143.1 424/144.1 424/145.1 514/44 530/387.1 530/387.3 530/388.15 530/388.22 530/388.23 536/24.5. A61K039/395 A61K035/00 C07H021/04 C07K016/24 C07K016/28.

☐ 52. [6465246](#). 20 Nov 98; 15 Oct 02. Oncogene- or virus-controlled expression systems. Mueller; Rolf, et al. 435/320.1; 435/325 435/375 435/69.1 435/69.7 435/91.1 435/91.4 530/352 530/358 536/23.1 536/23.4 536/23.5 536/23.72. C12N015/09 C12N015/85 C12N015/00 C12P021/06 C07H021/04.

☐ 53. [6455044](#). 14 Apr 99; 24 Sep 02. 5c8 antigen. Lederman; Seth, et al. 424/184.1; 514/2 514/8 514/885 530/350 530/387.1 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K038/17 C07K014/705 C07K016/28.

☐ 54. [6451310](#). 07 Jun 95; 17 Sep 02. Method for inhibiting an allergic response with a 5c8-specific antibody. Lederman; Seth, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.

☐ 55. [6447767](#). 16 Feb 00; 10 Sep 02. Non-myeloablative tolerogenic treatment. Slavin; Shimon, et al. 424/93.1; 424/93.21 435/325 514/2 514/44. A61K038/00 A61K048/00 C12N015/85.

☐ 56. [6440930](#). 16 Mar 01; 27 Aug 02. Protein formulations. Rinella, Jr.; Vincent Joseph. 514/2; 514/356. A61K038/00 A61K031/44.

☐ 57. [6432723](#). 21 Jan 00; 13 Aug 02. Biosensors utilizing ligand induced conformation changes. Plaxco; Kevin W., et al. 436/518; 204/400 205/777.5 422/82.01 422/82.02 422/82.03 435/287.1 435/287.2 435/6 435/7.1 436/149 436/151 436/536 436/537 436/806. G01N033/543.

☐ 58. [6429186](#). 19 Sep 94; 06 Aug 02. Ligand antagonists for treatment of breast cancer. Fuh; Germaine, et al. 514/2; 530/399. A01N037/18 A61K038/00 C07X014/00.

☐ 59. [6428782](#). 31 Dec 98; 06 Aug 02. Non-myeloablative tolerogenic treatment. Slavin; Shimon, et al. 424/93.1; 424/93.21 435/325 800/8. A61K038/00 C12N005/08.

☐ 60. [6426075](#). 30 Jul 99; 30 Jul 02. Protease-activatable pseudomonas exotoxin A-like proproteins. Fitzgerald; David J., et al. 424/260.1; 424/183.1 424/184.1 424/192.1 424/193.1 424/236.1 424/261.1 435/69.1 435/69.7 435/71.1 435/71.3 530/356 530/387.3 530/391.7. A61K039/108 A61K039/00 C12P021/04 C12P021/06 C12N015/09.

☐ 61. [6423513](#). 10 Jan 00; 23 Jul 02. Polynucleotides encoding protease-activatable pseudomonas exotoxin a-like proproteins. Fitzgerald; David J., et al. 435/71.3; 424/183.1 424/184.1 424/192.1 424/193.1 424/236.1 424/260.1 435/252.33 435/320.1 435/69.1 435/69.3 435/69.7 435/71.1 530/351 530/356 530/387.3 530/391.7. C12P021/04 C12P021/06 C12N015/09 A61K039/00.

- ☐ 62. 6417335. 03 Oct 00; 09 Jul 02. Protein purification. Basey; Carol D., et al. 530/387.1; 530/387.3 530/387.7 530/388.85 530/389.7 530/416. C07K001/18 C07K016/00.
-
- ☐ 63. 6413771. 18 Jun 99; 02 Jul 02. Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof. Brams; Peter, et al. 435/339; 424/147.1 424/159.1 424/192.1 424/211.1 435/5 435/7.1 530/388.3. C12N005/06 C12Q001/70 G01N033/53 C12P021/08 A61K039/42.
-
- ☐ 64. 6413514. 17 Dec 99; 02 Jul 02. Methods of using antibodies against human CD40. Aruffo; Alejandro A., et al. 424/144.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73. A61K039/395 C07K016/28.
-
- ☐ 65. 6410023. 09 Jul 99; 25 Jun 02. Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene. Durbin; Anna P., et al. 424/186.1; 424/184.1 424/185.1 424/199.1 424/211.1 424/212.1 435/252.3 435/320.1 435/440 435/69.1. A61K039/12 A61K039/00 A61K039/155 A61K039/165 C12P021/06.
-
- ☐ 66. 6403091. 07 Jun 95; 11 Jun 02. Methods for inhibiting the rejection of a transplant organ in a subject with 5C8-specific antibodies. Lederman; Seth, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 435/343 435/343.1 435/343.2 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
-
- ☐ 67. 6403090. 17 Jun 99; 11 Jun 02. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine. Cutler; Jim E., et al. 424/152.1; 424/130.1 424/141.1 530/388.1 530/388.4 530/388.5 530/389.1 530/389.5. A61K039/395 C07K016/00 C12P021/08.
-
- ☐ 68. 6391587. 17 Jun 99; 21 May 02. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine. Cutler; Jim E., et al. 435/69.3; 435/252.3 435/254.11 435/320.1 435/325 435/70.1 435/71.1 530/300 530/328 536/23.1. C12N015/09 C12N001/20 C07H021/02.
-
- ☐ 69. 6387377. 15 Dec 95; 14 May 02. Acellular antibordetella vaccine. Gueirard; Pascale, et al. 424/240.1; 424/184.1 424/234.1 424/236.1 424/253.1 424/254.1 424/93.1 424/93.3 435/183 435/232 435/243 435/252.1 435/814 514/44. A61K039/10 A61K039/02 C12N001/20 A01N043/00.
-
- ☐ 70. 6380366. 15 Feb 00; 30 Apr 02. Shark cartilage extract:process of making, methods of using and compositions thereof. Dupont; Eric, et al. 530/422; 424/548 424/549 530/350 530/400 530/412 530/414 530/415 530/417 530/418. A23J001/00.
-
- ☐ 71. 6372955. 01 Mar 00; 16 Apr 02. Methods for Producing B cells and antibodies from H2-O modified transgenic mice. Karlsson; Lars, et al. 800/4; 800/13 800/14 800/18 800/5 800/6. A01K067/00 A01K067/027 C12N015/00 C12P021/00.
-
- ☐ 72. 6368596. 08 Jul 98; 09 Apr 02. Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells. Ghetie; Maria-Ana, et al. 424/141.1; 424/130.1 424/133.1 424/134.1 424/136.1 424/138.1 424/139.1 424/142.1 424/152.1 424/155.1 424/156.1 424/172.1. A61K039/395 A61K039/40 A61K039/42.
-
- ☐ 73. 6352836. 04 Aug 00; 05 Mar 02. Dirofilaria and brugia thioredoxin peroxidase type-2 proteins and uses thereof. Chandrashekar; Ramaswamy, et al. 435/28; 424/184.1 424/265.1 435/183 514/44

530/300 530/350 536/23.5. C12Q001/28 C12N009/00 A61K038/00 A61K039/00 C07K001/00.

☐ 74. 6348327. 01 Mar 93; 19 Feb 02. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells. Gorman; Cornelia M., et al. 435/69.1; 435/320.1 435/325. C12P021/02 C12N015/63 C12N005/10.

☐ 75. 6340682. 23 Feb 99; 22 Jan 02. Diamide compound and drugs containing the same. Ishiwata; Hiroyuki, et al. 514/235.8; 514/218 514/249 514/252.11 514/252.18 514/253.01 514/253.05 514/253.06 514/254.05 514/254.08 514/254.09 514/255.01 540/575 544/121 544/295 544/350 544/353 544/357 544/360 544/363 544/364 544/365 544/370 544/373 544/387. A61K031/495 A61K031/55 A61P037/00 C07D241/04 C07D295/18.

☐ 76. 6339142. 03 Oct 00; 15 Jan 02. Protein purification. Basey; Carol D., et al. 530/387.3; 424/133.1 424/138.1 424/155.1 530/388.85. A61K039/395 C07K016/30.

☐ 77. 6333398. 06 Jun 00; 25 Dec 01. Protein purification. Blank; Gregory S.. 530/413; 530/387.3. C07K001/22.

☐ 78. 6331615. 07 Apr 99; 18 Dec 01. Nucleic acid molecule encoding heavy or light chain of an antibody which specifically recognizes a protein specifically recognized by monoclonal antibody 5c8 (anti-CD40 ligand). Lederman; Seth, et al. 536/23.53; 435/252.3 435/320.1 435/326 435/328 435/332 435/334 435/343 435/343.1 435/343.2 435/346 435/455 435/471 435/476 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75 536/23.1 536/23.5. C12N015/13 C12N015/12 C12N015/00 C07H021/04.

☐ 79. 6331433. 14 Apr 99; 18 Dec 01. Human T cell leukemia cell line designated D1.1. Lederman; Seth, et al. 435/325; 435/2. C12N005/06 C12N005/00.

☐ 80. 6322997. 14 Dec 99; 27 Nov 01. Protein recovery. Blank; Gregory S., et al. 435/68.1; 435/272 530/387.3 530/388.22 530/412 530/414 530/417. C07K001/34 C07K016/28 C12P021/06.

☐ 81. 6322972. 02 Nov 98; 27 Nov 01. TNF receptor death domain ligand proteins and inhibitors of ligand binding. Lin; Lih-Ling, et al. 435/6; 435/7.1 435/7.2. C12Q001/68 G01N033/53.

☐ 82. 6312693. 10 Feb 99; 06 Nov 01. Antibodies against human CD40. Aruffo; Alejandro A., et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/173.1 435/252.2 435/320.1 435/326 435/328 435/332 435/334 435/343 435/343.1 435/455 435/471 435/69.6 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 536/23.1 536/23.5 536/23.53. A61K039/395 C07K016/28 C12N015/13.

☐ 83. 6309642. 13 May 98; 30 Oct 01. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine. Cutler; Jim E., et al. 424/185.1; 424/184.1 424/274.1 514/15 514/2 530/300 530/328. A61K039/00.

☐ 84. 6290957. 21 Apr 99; 18 Sep 01. Anti-IgE antibodies and method of improving polypeptides. Lowman; Henry B., et al. 424/133.1; 424/153.1 424/810. A61K039/395.

☐ 85. 6290839. 14 Aug 98; 18 Sep 01. Systems for electrophoretic transport and detection of analytes. Kayyem; Jon Faiz, et al. 205/777.5; 204/403.14 204/409 204/450 204/452 204/600 204/603.

G01N027/26.

-
- ☐ 86. 6267958. 14 Mar 96; 31 Jul 01. Protein formulation. Andya; James, et al. 424/130.1; 424/138.1 424/141.1 424/143.1 424/145.1 424/155.1 435/810 514/2 530/350 530/387.1 530/387.7 530/388.1 530/388.22 530/388.8. A61K039/395 C07K016/00.
-
- ☐ 87. 6265542. 08 Oct 98; 24 Jul 01. Purification of molecules. Fahrner; Robert Lee, et al. 530/344; 210/656 530/412 530/415 530/416. C07K001/14 C07K001/16.
-
- ☐ 88. 6264825. 23 Jun 99; 24 Jul 01. Binding acceleration techniques for the detection of analytes. Blackburn; Gary, et al. 205/777.5; 204/403.01 204/409 204/450 204/452 204/600 204/603. G01N027/26.
-
- ☐ 89. 6258560. 29 Jun 00; 10 Jul 01. Process for bacterial production of polypeptides. Leung; Woon-Lam Susan, et al. 435/69.1; 435/252.1 435/252.3 435/320.1 435/69.7. C12P021/00 C12N015/09 C12N001/20.
-
- ☐ 90. 6252050. 10 Jun 99; 26 Jun 01. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method. Ashkenazi; Avi J., et al. 530/387.3; 424/143.1 424/174.1 435/334 436/548 530/388.15 530/388.22 530/389.1. A61K039/395 C07K016/28.
-
- ☐ 91. 6242195. 02 Apr 98; 05 Jun 01. Methods for determining binding of an analyte to a receptor. Idusogie; Esohe Ekinaduese, et al. 435/7.1; 435/7.2 435/7.23 436/63. G01N033/53 G01N033/567 G01N033/574 G01N033/48.
-
- ☐ 92. 6228983. 07 Jun 95; 08 May 01. Human respiratory syncytial virus peptides with antifusogenic and antiviral activities. Barney; Shawn O'Lin, et al. 530/300; 424/186.1 424/211.1 530/324 530/325 530/326. A61K038/00.
-
- ☐ 93. 6210662. 24 Jun 99; 03 Apr 01. Immunostimulatory composition. Laus; Reiner, et al. 424/93.1; 435/325 435/366 435/372 435/372.3. A01N063/00 A01N065/00 C12N005/00 C12N005/08.
-
- ☒ 94. 6207159. 21 Jul 98; 27 Mar 01. Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus. Kaufman; Daniel L., et al. 424/184.1; 424/278.1 424/283.1 424/520 424/556 424/572 424/810 424/93.7 514/2 514/21 514/3 514/4 514/866 530/351 530/403. A61K039/00 A61K045/00 A61K038/28 A61K038/43 A01N063/00.
-
- ☐ 95. 6197927. 06 Mar 98; 06 Mar 01. Peptide variants of protein A. Braisted; Andrew C., et al. 530/317; 424/192.1 424/193.1 424/194.1 530/324 530/350. C07K005/12.
-
- ☐ 96. 6197926. 23 Feb 99; 06 Mar 01. Methods for treatment of diabetes using peptide analogues of insulin. Gaur; Amitabh, et al. 530/303; 435/69.4 530/326. C07K014/62 C07K014/00 A61K038/28.
-
- ☐ 97. 6194551. 31 Mar 99; 27 Feb 01. Polypeptide variants. Idusogie; Esohe Ekinaduese, et al. 530/387.1; 530/388.15 530/388.22 530/388.23 530/388.25 530/388.7 530/389.1. C07K014/00 C07K016/00 C12P021/08.
-
- ☐ 98. 6187552. 23 Mar 98; 13 Feb 01. Method for identifying inhibitors of JAK2/cytokine receptor binding. Roberds; Steven L., et al. 435/7.93; 435/7.9 435/7.92. G01N033/53.
-

☐ 99. 6180401. 04 May 98; 30 Jan 01. Polypeptide production in animal cell culture. Chen; Mary, et al. 435/358; 435/325. C12N005/00 C12N005/06.

☐ 100. 6180367. 21 Oct 99; 30 Jan 01. Process for bacterial production of polypeptides. Leung; Woon-Lam Susan, et al. 435/69.1; 435/252.1 435/252.3 435/69.7. C12P021/00.

[Generate Collection](#)[Print](#)

Terms	Documents
15 and 16	221

[Previous Page](#)[Next Page](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 101 through 150 of 221 returned.**

-
- ☐ 101. [6172213](#). 30 Jun 98; 09 Jan 01. Anti-IgE antibodies and method of improving polypeptides. Lowman; Henry B., et al. 536/23.53; 435/252.3 435/320.1 435/69.6 530/387.3 530/388.73. C07H021/04 C12P021/08 C07K016/00 C12N015/00 C12N001/20.
-
- ☐ 102. [6171586](#). 12 Jun 98; 09 Jan 01. Antibody formulation. Lam; Xanthe M., et al. 424/130.1; 424/141.1 424/152.1 424/154.1 424/173.1 530/388.75. A61K039/395 C12P021/08.
-
- ☐ 103. [6159462](#). 15 Aug 97; 12 Dec 00. Uses of Wnt polypeptides. Matthews; William, et al. 424/85.1; 424/85.2 435/383 435/395 435/404 435/405 435/406 514/2 514/814 530/350 530/351 530/868. A61K045/05 C12N005/02 A01N037/18 C07K001/00.
-
- ☐ 104. [6156312](#). 18 Jan 96; 05 Dec 00. Agents, affecting the hyperactivated immunological effector cells. Leskovar; Peter. 424/144.1;. A61K039/395.
-
- ☐ 105. [6150584](#). 02 Oct 96; 21 Nov 00. Human antibodies derived from immunized xenomice. Kucherlapati; Raju, et al. 800/18; 424/93.21 800/25 800/6. A61K048/00 C12N005/10 C12N015/07.
-
- ☐ 106. [6150135](#). 23 May 97; 21 Nov 00. Dirofilaria and brugia thioredoxin peroxidase type-2 (TPX-2) nucleic acid molecules, and uses thereof. Chandrashekar; Ramaswamy, et al. 435/69.3; 435/235.1 435/252.3 435/320.1 435/325 514/44 536/23.5. C12N015/09 C12N007/00 C12N015/00 C07H021/04.
-
- ☐ 107. [6150093](#). 18 Feb 97; 21 Nov 00. Unique associated Kaposi's sarcoma virus sequences and uses thereof. Chang; Yuan, et al. 435/6; 435/235.1 435/252.3 435/320.1 435/325 536/23.1 536/24.32. C12Q001/68 C12N005/10 C12N007/00 C12N015/63.
-
- ☐ 108. [6140128](#). 20 Dec 99; 31 Oct 00. Preparation of calcium phosphate transfectacons. Cohen; Darien L., et al. 435/455; 435/320.1 536/23.1. C12N015/64.
-
- ☐ 109. [6127526](#). 20 Nov 97; 03 Oct 00. Protein purification by Protein A chromatography. Blank; Gregory S.. 530/413;. C07K001/22.
-
- ☐ 110. [6121428](#). 12 Jun 98; 19 Sep 00. Protein recovery. Blank; Gregory S., et al. 530/413; 435/269 435/272 530/344 530/412 530/414 530/417. C07K001/22 C07K001/34.
-
- ☐ 111. [6121022](#). 14 Apr 95; 19 Sep 00. Altered polypeptides with increased half-life. Presta; Leonard G., et al. 435/69.7; 435/320.1 435/328 435/334 435/69.6 530/350 530/387.3 530/388.22 536/23.4 536/23.53. C07K016/00 C12N015/13 C12N015/62.
-
- ☐ 112. [6117840](#). 14 Apr 97; 12 Sep 00. CS-1 peptidomimetics, compositions and methods of using the same. Arrhenius; Thomas S., et al. 514/19; 514/18 530/330 530/331 562/571. A61K038/05.
-
- ☐ 113. [6114137](#). 14 Oct 97; 05 Sep 00. Assay using marked microbial host cell strains. McFarland; Nancy C., et al. 435/39; 435/252.3 435/252.33 435/254.11 435/254.2 435/29 435/320.1 435/34 435/38 435/440 435/462. C12Q001/06 C12Q001/04 C12N001/20 C12N015/00.

-
- ☐ 114. 6103870. 03 Sep 97; 15 Aug 00. CS-1 peptidomimetic, compositions and methods of using the same. Arrhenius; Thomas S., et al. 530/331; 530/330. A61K038/06.
-
- ☐ 115. 6096871. 14 Apr 95; 01 Aug 00. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life. Presta; Leonard G., et al. 530/387.3; 424/133.1 424/145.1 435/328 435/69.6 435/69.7 530/388.23. A61K039/395 C07K016/00.
-
- ☐ 116. 6093794. 07 Jun 95; 25 Jul 00. Isolated peptides derived from the Epstein-Barr virus containing fusion inhibitory domains. Barney; Shawn O'Lin, et al. 530/300; 424/186.1 424/230.1 530/324 530/325 530/326 530/350. A61K038/00 A61K039/12 A61K039/245.
-
- ☐ 117. 6086902. 09 Sep 94; 11 Jul 00. Recombinant bovine herpesvirus type 1 vaccines. Zamb; Timothy, et al. 424/209.1; 424/204.1 424/205.1. A01N037/18.
-
- ☐ 118. 6083919. 05 Dec 97; 04 Jul 00. Materials and methods for treating autoimmune disease. Johnson; Howard M., et al. 514/21; 424/85.4. A61K038/00 A61K038/21.
-
- ☐ 119. 6080409. 28 Dec 95; 27 Jun 00. Immunostimulatory method. Laus; Reiner, et al. 424/192.1; 424/193.1 424/194.1 424/195.11 424/198.1 514/2. A61K039/00 A61K039/385 A61K038/00 A01N037/18.
-
- ☐ 120. 6068973. 07 Jun 95; 30 May 00. Methods for inhibition of membrane fusion-associated events, including influenza virus. Barney; Shawn O'Lin, et al. 435/5; 424/147.1 424/206.1 424/230.1 530/324 530/389.4. C12Q001/70 A61K038/00 A61K039/42 C07K016/00.
-
- ☐ 121. 6060065. 07 Jun 95; 09 May 00. Compositions for inhibition of membrane fusion-associated events, including influenza virus transmission. Barney; Shawn O'Lin, et al. 424/209.1; 424/186.1 424/192.1 424/206.1 530/300 530/324 530/325 530/326 530/327 530/328 530/329 530/330. A61K039/145 A61K039/12 A61K039/00 A61K038/00.
-
- ☐ 122. 6051228. 19 Feb 98; 18 Apr 00. Antibodies against human CD40. Aruffo; Alejandro A., et al. 424/144.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/153.1 424/173.1 435/252.3 435/320.1 435/452 530/387.1 530/387.3 530/388.2 530/388.22 530/388.7 530/388.73 536/23.53. A61K039/395 C07K016/28 C12N015/13 C12N001/21.
-
- ☐ 123. 6040136. 03 Sep 97; 21 Mar 00. Enrichment method for variant proteins with altered binding properties. Garrard; Lisa J., et al. 435/5; 435/235.1 435/239 435/320.1 435/68.1 435/69.1 435/69.7 435/69.8 436/802 530/350 530/387.1 530/387.9 536/24.1. C12Q001/70 C12P021/06 C07K014/00 C07H017/00.
-
- ☐ 124. 6030625. 23 Apr 98; 29 Feb 00. Bordetella pertussis and Bordetella parapertussis strains. Gueirard; Pascale, et al. 424/253.1; 424/184.1 424/234.1 424/240.1 424/254.1 424/93.1 424/93.4 435/243 435/252.1. A61K039/00 A61K039/02 A61K039/10 A01N063/00 C12N001/00.
-
- ☐ 125. 6030609. 19 May 95; 29 Feb 00. Method and composition for treating paramyxovirus. Panuska; James R., et al. 424/85.6; 424/85.4 435/235.1 435/243 435/69.51. C07K014/52 C07K014/555 A61K038/19 A61K038/21.
-

- ☐ 126. [6028186](#). 07 Jun 95; 22 Feb 00. High affinity nucleic acid ligands of cytokines. Tasset; Diane, et al. 536/24.31; 435/6 435/91.2 536/22.1 536/23.1 536/24.3. C07H021/02 C07H021/04 C12Q001/68 C12P019/34.
-
- ☐ 127. [6022697](#). 09 Jul 97; 08 Feb 00. Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus. Kaufman; Daniel L., et al. 435/7.24; 435/7.92 436/501 436/506 530/350 530/351. G01N033/53 G01N033/564 C07K001/00.
-
- ☐ 128. [6017536](#). 20 Dec 94; 25 Jan 00. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities. Barney; Shawn O'Lin, et al. 424/188.1; 424/208.1 530/300 530/324 530/325 530/326. A61K039/21.
-
- ☐ 129. [6013763](#). 04 Jun 96; 11 Jan 00. Peptide variants of protein A. Braisted; Andrew C., et al. 530/317; 436/828 530/321 530/324. C07K014/00.
-
- ☐ 130. [6013263](#). 07 Jun 95; 11 Jan 00. Measles virus peptides with antifusogenic and antiviral activities. Barney; Shawn O'Lin, et al. 424/212.1; 424/184.1 424/186.1 530/300 530/324 530/325 530/326. A61K039/165.
-
- ☐ 131. [6011002](#). 08 Jan 97; 04 Jan 00. Circularly permuted ligands and circularly permuted chimeric molecules. Pastan; Ira, et al. 514/2; 436/501 514/12 530/350 530/351 530/395 530/397 530/399. C07K014/00 A61K038/16.
-
- ☐ 132. [6004554](#). 02 Dec 94; 21 Dec 99. Methods for targeting the vasculature of solid tumors. Thorpe; Philip E., et al. 424/178.1; 424/136.1 424/181.1 424/182.1 424/183.1. A61K039/395 A61K039/40 A61K039/42.
-
- ☐ 133. [5994511](#). 02 Jul 97; 30 Nov 99. Anti-IgE antibodies and methods of improving polypeptides. Lowman; Henry B., et al. 530/387.3; 424/133.1 424/135.1 424/145.1 424/810 436/548 530/388.25 530/868. A61K039/395 C07K016/42.
-
- ☐ 134. [5993816](#). 07 Jun 95; 30 Nov 99. Methods to inhibit humoral immune responses, immunoglobulin production and B cell activation with 5c8-specific antibodies. Lederman; Seth, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/142.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.15 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
-
- ☐ 135. [5985286](#). 25 Nov 97; 16 Nov 99. Bordetella strains. Gueirard; Pascale, et al. 424/240.1; 424/253.1 424/254.1 424/255.1 424/93.1 424/93.4 435/183 435/232 435/243 435/252.1 435/71.2 435/814. A61K039/10 A61K039/102 C12N005/02 C12N001/20.
-
- ☐ 136. [5976546](#). 03 Sep 98; 02 Nov 99. Immunostimulatory compositions. Laus; Reiner, et al. 424/192.1; 424/193.1 424/194.1 424/195.11 530/350 530/351. A61K039/00 A61K039/385 C07K001/00 C07K014/00.
-
- ☐ 137. [5972599](#). 07 Jun 95; 26 Oct 99. High affinity nucleic acid ligands of cytokines. Tasset; Diane, et al. 435/6; 435/91.2 530/351 536/22.1 536/25.4. C12Q001/68 C12Q019/34 C07H021/04 C07H021/02.
-
- ☐ 138. [5968767](#). 05 Jun 97; 19 Oct 99. Methods for in vitro protein synthesis. Sheikh; Amina, et al.

435/68.1; 435/317.1 435/820. C12P021/00 C12N001/00 C07K014/00.

☐ 139. 5962274. 13 Mar 98; 05 Oct 99. Viral vector directed to predetermined target cells. Parks; Griffith D.. 435/91.1; 435/91.32 435/91.33 536/23.1 536/23.4 536/23.72 536/24.1. C12P019/34 C07H021/04.

☐ 140. 5962252. 10 Sep 97; 05 Oct 99. Assay using marked microbial host cell strains. McFarland; Nancy C., et al. 435/34; 435/29. C12Q001/04 C12Q001/02.

☐ 141. 5958765. 19 Dec 96; 28 Sep 99. Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof. Brams; Peter, et al. 435/339; 424/133.1 424/147.1 424/159.1 424/211.1 435/252.3 435/339.1 530/388.3. C12N005/00 C12N001/20 C07K016/00 A61K039/155.

☐ 142. 5955364. 18 Apr 96; 21 Sep 99. Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof. Brams; Peter, et al. 435/440; 424/133.1 424/147.1 424/211.1 536/23.53. C12N015/00 A61K039/395 A61K039/42 C07H021/04.

☐ 143. 5948638. 23 Apr 97; 07 Sep 99. TNF receptor death domain ligand proteins. Lin; Lih-Ling, et al. 435/69.1; 435/252.3 435/254.11 435/320.1 435/325 530/350 530/351 536/23.1 536/23.5. C12N015/12 C12N005/10 C12N015/10 C07K014/47.

☐ 144. 5945401. 23 Jun 95; 31 Aug 99. Peptide analogues of the 65KD isoform of human glutamic acid decarboxylase and uses thereof. Conlon; Paul J., et al. 514/14; 530/323 530/326 530/327 530/329. A61K038/43.

☐ 145. 5939068. 18 Apr 96; 17 Aug 99. Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof. Brams; Peter, et al. 424/133.1; 424/147.1 435/5 530/388.5 536/23.53. A61K039/395 A61K039/42 C12N015/00 C07H021/04.

☐ 146. 5936065. 05 Jun 95; 10 Aug 99. CS-1 peptidomimetics, compositions and methods of using the same. Arrhenius; Thomas S., et al. 530/331; 530/330. C07K005/08.

☐ 147. 5891675. 23 Apr 97; 06 Apr 99. TNF receptor death domain ligand proteins. Lin; Lih-Ling, et al. 435/69.1; 435/252.3 435/320.1 530/350 536/23.5. C07K014/705 C12N015/12.

☒ 148. 5891435. 16 Apr 93; 06 Apr 99. Methods and compositions for delaying or preventing the onset of autoimmune disease. Muir; Andrew, et al. 424/185.1; 424/198.1 530/300 530/350 530/399. A61K038/28.

☐ 149. 5882644. 22 Mar 96; 16 Mar 99. Monoclonal antibodies specific for the platelet derived growth factor .beta. receptor and methods of use thereof. Chang; Chung Nan, et al. 424/143.1; 424/133.1 530/387.3 530/388.22. A61K039/395.

☐ 150. 5877210. 05 Jun 95; 02 Mar 99. Phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation. Schieven; Gary L.. 514/492; 424/178.1 424/179.1 424/181.1 435/184 435/244 556/1 556/42 556/44. A01N055/02 A61K039/395 C07F053/00.
